Leading Pharma Third Party Manufacturer

Banned Fixed Dose Combinations (FDCs) in India 2026: What Pharma Third-Party Manufacturing Companies Must Know

India bans 16 Fixed Dose Combinations in 2026. Learn how this impacts pharma third-party manufacturing, contract manufacturers, and pharma businesses.

PHARMACEUTICAL BUSINESS

jp sharma

7/5/20265 min read

Banned Fixed Dose Combinations (FDCs) in India 2026: What Pharma Third-Party Manufacturing Companies Must Know

The Government of India has once again taken a significant step towards improving patient safety by banning several irrational Fixed Dose Combinations (FDCs) under the Drugs and Cosmetics Act, 1940. The notification, issued on 11 June 2026, prohibits the manufacture, sale, and distribution of 16 Fixed Dose Combinations (FDCs) with immediate effect.

For businesses involved in pharma third-party manufacturing, contract manufacturing, PCD pharma, and pharmaceutical marketing, this update is extremely important. Companies must immediately review their product portfolios to ensure compliance with the latest regulations.

In this article, we'll explain the newly banned FDCs, why they were prohibited, and how they affect pharmaceutical manufacturers and marketers.

What is a Fixed Dose Combination (FDC)?

A Fixed Dose Combination (FDC) is a pharmaceutical product that contains two or more active ingredients in a fixed ratio within a single dosage form.

When scientifically justified, FDCs offer several benefits:

  • Better patient compliance

  • Reduced pill burden

  • Improved therapeutic outcomes

  • Simplified treatment protocols

However, irrational combinations may expose patients to unnecessary risks without providing additional clinical benefits.

Why Has the Government Banned These FDCs?

The Ministry of Health & Family Welfare acted under Section 26A of the Drugs and Cosmetics Act, 1940 after recommendations from:

  • Expert Committee

  • Drugs Technical Advisory Board (DTAB)

The committee concluded that these combinations:

  • Lack therapeutic justification

  • May increase adverse effects

  • Offer no additional clinical advantage

  • Have safer alternatives available

  • May contribute to irrational prescribing practices

Therefore, their manufacture, sale, and distribution have been prohibited with immediate effect.

Complete List of Banned Fixed Dose Combinations (2026) Download Gazette Copy

The following combinations are no longer permitted for manufacture or sale in India:

S.NoFixed Dose Combination1Acetyl Salicylic Acid + Ethoheptazine2Aloe vera + Jojoba Oil + Wheat Germ Oil + Tea Tree Oil3Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes4Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide5Amoxicillin + Serratiopeptidase6Aloe Extract + Allantoin + Alphatocopherol Acetate + D-Panthenol + Vitamin A7Aloe Extract + Vitamin E + Dimethicone + Glycerine8Aloe vera + Jojoba Oil + Vitamin E9Aloe vera + Orange Oil10Aloe vera + Vitamin E + Herbal11Dicyclomine + Paracetamol + Clidinium Bromide12Paracetamol + Lignocaine13Gliclazide + Chromium Picolinate14Cefadroxyl + Probenecid15Amoxicillin + Cloxacillin + Lactic Acid Bacillus + Serratiopeptidase16Cefuroxime + Serratiopeptidase

Impact on Pharma Third-Party Manufacturing Companies

The latest notification directly affects companies engaged in pharma third-party manufacturing. Manufacturers producing any of these banned combinations for clients must stop manufacturing immediately.

Major implications include:

Immediate Product Review

Manufacturers should review all existing formulations and identify products containing banned combinations.

Production Must Stop

No new batches of these FDCs should be manufactured after the notification comes into effect.

Inventory Management

Existing stock should be managed according to regulatory directions issued by the licensing authorities.

Client Communication

Third-party manufacturers should promptly inform their marketing partners, distributors, and PCD franchise companies about the regulatory changes.

Regulatory Compliance

Maintaining updated regulatory knowledge helps pharmaceutical companies avoid legal complications and strengthens their market reputation.

What Should Pharma Marketing Companies Do?

If your business markets pharmaceutical products manufactured through pharma third-party manufacturing, you should:

  • Review your product catalogue.

  • Verify formulations with your manufacturing partner.

  • Stop promoting banned products.

  • Replace irrational combinations with approved alternatives.

  • Educate your sales team about the latest regulatory updates.

Importance of Choosing a Regulatory-Compliant Pharma Third-Party Manufacturing Partner

Selecting the right pharma third-party manufacturing company is about more than manufacturing capacity. A reliable partner should:

  • Follow WHO-GMP manufacturing standards.

  • Maintain strong regulatory compliance.

  • Continuously monitor CDSCO and Ministry notifications.

  • Update formulations as per current guidelines.

  • Maintain robust quality assurance systems.

  • Assist clients with regulatory documentation.

Working with a compliant manufacturer reduces business risk and protects your brand's reputation.

How Ogiso Life Sciences Ensures Regulatory Compliance

At Ogiso Life Sciences Pvt. Ltd., regulatory compliance is a core part of our manufacturing process. Our team continuously tracks updates from Indian drug regulatory authorities to ensure that every product manufactured under our pharma third-party manufacturing services complies with applicable laws and quality standards.

We help pharmaceutical companies develop compliant, market-ready formulations while maintaining high manufacturing quality and transparency throughout the production process.

Conclusion

The 2026 ban on these irrational Fixed Dose Combinations highlights the government's continued commitment to promoting rational drug use and patient safety. Pharmaceutical manufacturers, marketers, and distributors must remain vigilant and ensure their product portfolios comply with the latest regulations.

For businesses relying on pharma third-party manufacturing, choosing a manufacturing partner that prioritizes regulatory compliance is essential for long-term success.

By staying informed and adapting quickly to regulatory updates, pharmaceutical companies can continue to build trust, ensure patient safety, and maintain sustainable business growth.

Frequently Asked Questions (FAQs)

Are these FDCs banned immediately?

Yes. The Government notification states that the manufacture, sale, and distribution of these combinations are prohibited with immediate effect.

Why were these combinations banned?

They were found to lack therapeutic justification, may increase unnecessary health risks, and safer alternatives are available.

Does this affect pharma third-party manufacturing companies?

Yes. Any manufacturer producing these banned formulations must discontinue their manufacture and comply with regulatory requirements.

Can pharmaceutical companies replace these formulations?

Yes. Companies should consult regulatory experts and develop scientifically justified, approved formulations instead of banned combinations.

  • Pharma Third-Party Manufacturing Services

  • Contract Manufacturing Services

  • How to Start a Pharma Company in India

  • WHO-GMP Certified Pharmaceutical Manufacturing

  • PCD Pharma Franchise Opportunities

  • Quality Assurance & Manufacturing Process

  • Our Product Portfolio

  • Contact Us

Useful Links:

Disclaimer:

The information provided in this article is intended solely for educational and informational purposes. While every effort has been made to ensure the accuracy and reliability of the content at the time of publication, pharmaceutical regulations, government notifications, and legal requirements may change without prior notice.

This article is based on the Gazette Notification issued by the Ministry of Health & Family Welfare, Government of India, dated 11 June 2026, regarding the prohibition of certain Fixed Dose Combinations (FDCs) under Section 26A of the Drugs and Cosmetics Act, 1940. Readers are advised to verify the latest notifications, amendments, and official guidelines before making any business, regulatory, manufacturing, marketing, or healthcare decisions.

The list of banned Fixed Dose Combinations presented in this article is provided for general awareness only and should not be considered a substitute for the official Gazette notification or professional regulatory advice. Pharmaceutical manufacturers, marketers, distributors, healthcare professionals, and other stakeholders should consult the relevant regulatory authorities or qualified legal and regulatory experts for guidance specific to their circumstances.

This content does not constitute medical, legal, regulatory, or professional advice. Patients should never start, stop, or modify any medication without consulting a qualified registered medical practitioner.

Ogiso Life Sciences Pvt. Ltd., its management, employees, authors, and affiliates shall not be held liable for any direct or indirect loss, damage, claim, or consequence arising from the use of, reliance on, or interpretation of the information contained in this article.

References to government organizations, regulatory authorities, products, or pharmaceutical ingredients are made solely for informational purposes and do not imply any endorsement, affiliation, or recommendation.

For the most current and authentic regulatory information, readers should refer to the official publications of the Ministry of Health & Family Welfare, the Central Drugs Standard Control Organisation (CDSCO), and the Gazette of India.

Author:
Mr. JP Sharma
22+ years of experience in pharmaceutical manufacturing and trading.